Is topical insulin an appropriate treatment for diabetic foot ulcers?

Topical Insulin for Diabetic Foot Ulcers

Do not use topical insulin for diabetic foot ulcers—it is not recommended by current evidence-based guidelines and lacks sufficient high-quality evidence to support its routine use.

Guideline-Based Recommendation

The most recent and authoritative 2024 IWGDF (International Working Group on the Diabetic Foot) guidelines explicitly do not recommend topical insulin for diabetic foot ulcers 1. While topical insulin is not specifically listed among the "do not use" recommendations, it falls under the category of interventions lacking sufficient evidence for inclusion as a recommended therapy. The guidelines provide a comprehensive list of what should and should not be used, and topical insulin is notably absent from any positive recommendations.

What the Guidelines Actually Recommend:

Standard of care should include:

• Sharp debridement (frequency determined by clinical need)
• Basic wound dressings that absorb exudate and maintain a moist wound environment
• Appropriate off-loading

Conditional considerations only after standard care has failed:

• Sucrose-octasulfate impregnated dressing (for non-infected neuro-ischemic ulcers after ≥2 weeks of failed standard care)
• Hyperbaric oxygen (for neuro-ischemic/ischemic ulcers where resources exist)
• Autologous leucocyte, platelet, and fibrin patch
• Placental-derived products

The Research Evidence Paradox

While recent research studies suggest potential benefits of topical insulin 2, 3, 4, 5, these findings have not translated into guideline recommendations for critical reasons:

Why Research Hasn't Changed Practice:

1. Low certainty of evidence: The 2026 systematic review 2 explicitly states the evidence is "low or very low certainty" due to high risk of bias and methodological limitations

2. Inconsistent methodology: Studies used varying insulin concentrations, application methods, and outcome measures, making it impossible to establish a standardized protocol

3. Small, single-center trials: Most studies were conducted at individual institutions with small sample sizes, limiting generalizability

4. Lack of long-term outcomes: No studies adequately assessed amputation rates, mortality, or quality of life—the outcomes that truly matter

What the Research Actually Shows:

A 2026 meta-analysis 2 found topical insulin may reduce:

• Time to wound healing by approximately 6 days
• Wound size by approximately 3.39 cm²

However, another 2026 study 6 found medicinal honey superior to topical insulin, yet the IWGDF guidelines explicitly recommend against honey 1 (Strong recommendation, Low evidence). This highlights the disconnect between individual study results and evidence-based practice.

Clinical Algorithm

For any diabetic foot ulcer:

1. Implement standard of care first (this is non-negotiable):

   • Sharp debridement
   • Moisture-retentive dressing (absorbs exudate, maintains moist environment)
   • Appropriate off-loading
   • Infection control if needed
   • Vascular assessment and optimization

2. Reassess at 2 weeks:

   • If healing progresses: continue standard care
   • If insufficient progress: consider evidence-based adjuncts

3. For non-infected neuro-ischemic ulcers with failed standard care:

   • Consider sucrose-octasulfate dressing (Conditional recommendation, Moderate evidence) 1

4. For ischemic ulcers where standard care has failed:

   • Consider hyperbaric oxygen (if resources exist) 1
   • Consider topical oxygen therapy (if resources exist) 1

5. Do NOT use (Strong recommendations):

   • Topical antiseptic/antimicrobial dressings 1
   • Honey or bee products 1
   • Collagen or alginate dressings 1
   • Topical phenytoin 1
   • Herbal remedies 1

Critical Pitfalls to Avoid

The "promising research" trap: Just because recent studies show statistical significance doesn't mean the intervention improves morbidity, mortality, or quality of life. The IWGDF guidelines prioritize these patient-centered outcomes over surrogate markers like wound size reduction.

Off-label insulin use concerns: FDA-approved insulin formulations 7 are indicated for glycemic control, not topical wound application. Using insulin topically is off-label and carries medicolegal considerations.

Resource allocation: Money and effort spent on unproven therapies like topical insulin diverts resources from interventions with stronger evidence (proper off-loading, vascular optimization, sharp debridement).

False hope: Offering topical insulin may delay appropriate surgical intervention or vascular revascularization when these are truly needed.

The Bottom Line

Despite mechanistically plausible benefits and some positive research findings, topical insulin has not met the evidentiary threshold for guideline inclusion. The 2024 IWGDF guidelines 1 represent the most comprehensive, recent, and authoritative source for diabetic foot ulcer management. Stick to proven standard care and evidence-based adjuncts when standard care fails. If you want to improve outcomes for diabetic foot ulcers, focus on what we know works: aggressive sharp debridement, proper off-loading, and vascular optimization—not experimental topical therapies lacking robust evidence.